Involvement of actin cytoskeletal modifications in the inhibition of triple-negative breast cancer growth and metastasis by nimbolide.
Rac1/Cdc42
actin cytoskeleton
actin depolymerization
integrin-FAK
metastasis
nimbolide
triple-negative breast cancer
Journal
Molecular therapy oncolytics
ISSN: 2372-7705
Titre abrégé: Mol Ther Oncolytics
Pays: United States
ID NLM: 101666776
Informations de publication
Date de publication:
26 Mar 2021
26 Mar 2021
Historique:
received:
07
03
2020
accepted:
18
02
2021
entrez:
26
3
2021
pubmed:
27
3
2021
medline:
27
3
2021
Statut:
epublish
Résumé
Triple-negative breast cancers (TNBCs) are aggressive cancers, which currently do not have effective treatment options. Migration and establishment of metastatic colonies require dynamic cytoskeletal modifications characterized by polymerization and depolymerization of actin. Studies have demonstrated a direct molecular link between the integrin-focal adhesion kinase (FAK) pathway and cytoskeletal modifications. Nimbolide, a major bioactive compound present in neem leaves, shows promising anti-cancer effect on various cancers. In this study, we have demonstrated the growth and metastasis inhibitory potential of nimbolide on TNBC cells. Nimbolide inhibited cell proliferation, migratory, and invasive abilities of TNBC cells and also changed the shape of MDA-MB-231 cells, which is correlated with cytoskeletal changes including actin depolymerization. Furthermore, analysis revealed that integrins αV and β3, ILK, FAK, and PAK levels were downregulated by nimbolide. Even in cells where Rac1/Cdc42 was constitutively activated, nimbolide inhibited the formation of filopodial structures. Immunofluorescence analysis of phosphorylated p21 activated kinase (pPAK) showed reduced expression in nimbolide-treated cells. Nimbolide significantly reduced the metastatic colony formation in lung, liver, and brain of athymic nude mice. In conclusion, our data demonstrate that nimbolide inhibits TNBC by altering the integrin and FAK signaling pathway.
Identifiants
pubmed: 33768141
doi: 10.1016/j.omto.2021.02.014
pii: S2372-7705(21)00032-2
pmc: PMC7972938
doi:
Types de publication
Journal Article
Langues
eng
Pagination
596-606Informations de copyright
© 2021 The Authors.
Déclaration de conflit d'intérêts
The authors declare no competing interests.
Références
Nat Rev Mol Cell Biol. 2014 Sep;15(9):577-90
pubmed: 25145849
Int J Cancer. 2011 Jun 1;128(11):2527-35
pubmed: 21365651
Front Oncol. 2018 Feb 22;8:31
pubmed: 29520340
Annu Rev Biochem. 2003;72:743-81
pubmed: 12676796
Mol Biol Cell. 2002 Jul;13(7):2533-46
pubmed: 12134088
Toxicol In Vitro. 2014 Aug;28(5):1026-35
pubmed: 24759803
Lancet. 2005 May 14-20;365(9472):1687-717
pubmed: 15894097
Oncotarget. 2016 Jul 12;7(28):44790-44802
pubmed: 27027349
Adv Biol Regul. 2015 Jan;57:10-6
pubmed: 25482988
Biomed Pharmacother. 2017 Aug;92:340-346
pubmed: 28554129
Sci Rep. 2016 Jan 25;6:19819
pubmed: 26804739
Exp Cell Res. 2016 Apr 10;343(1):7-13
pubmed: 26515553
Curr Opin Cell Biol. 2013 Oct;25(5):613-8
pubmed: 23797029
J Biol Chem. 2006 May 5;281(18):12397-407
pubmed: 16531412
N Engl J Med. 2008 Dec 25;359(26):2814-23
pubmed: 19109576
Trends Cancer. 2015 Sep;1(1):76-91
pubmed: 28741564
Proc Natl Acad Sci U S A. 2002 Jun 25;99(13):8562-7
pubmed: 12077320
J Biol Chem. 2000 Jul 28;275(30):23106-12
pubmed: 10767298
Phytother Res. 2007 Mar;21(3):245-50
pubmed: 17163581
Nat Rev Mol Cell Biol. 2014 Dec;15(12):802-12
pubmed: 25355505
Radiol Oncol. 2011 Mar;45(1):46-52
pubmed: 22933934
Sci Rep. 2017 May 17;7(1):2045
pubmed: 28515436
Nat Cell Biol. 2015 Dec;17(12):1577-1587
pubmed: 26479319
Int J Mol Sci. 2015 Sep 29;16(10):23405-24
pubmed: 26426012
Front Oncol. 2018 May 04;8:145
pubmed: 29780748
Antioxid Redox Signal. 2016 Apr 10;24(11):575-89
pubmed: 26649526
J Cell Sci. 2009 Jan 15;122(Pt 2):187-98
pubmed: 19118211
J Biol Chem. 2010 Nov 12;285(46):35406-17
pubmed: 20829362
Mol Carcinog. 2012 Jun;51(6):475-90
pubmed: 21678498
Curr Opin Cell Biol. 2009 Oct;21(5):670-5
pubmed: 19560331
Science. 1999 Aug 13;285(5430):1028-32
pubmed: 10446041
Curr Opin Cell Biol. 2009 Feb;21(1):28-37
pubmed: 19168341
Cancer Chemother Pharmacol. 2013 Apr;71(4):829-42
pubmed: 23377372
Nat Rev Cancer. 2009 Apr;9(4):274-84
pubmed: 19308067
J Cell Sci. 2016 Nov 15;129(22):4159-4163
pubmed: 27799358
Eur J Pharmacol. 2012 Apr 15;681(1-3):6-14
pubmed: 22327045
FEBS J. 2017 Oct;284(20):3355-3361
pubmed: 28796323
Br J Pharmacol. 2014 Dec;171(24):5507-23
pubmed: 24665826
Acta Biochim Pol. 2009;56(2):225-34
pubmed: 19513348